GlassScriptPhysician profile
Ian Horkheimer
NPI 1316924772
$1,222.05
in general payments reported to CMS, 2019-2025
20 companies · $726 in 2025
The $726 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $14.92 · 2021: $25.09 · 2022: $51.97 · 2023: $50.04 · 2024: $164 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $475 · Food and Beverage: $341 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $475.00 |
| Food and Beverage | $341.04 |
| Education | $124.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $489.66 | 2024-2025 | |
| Gilead Sciences, INC. | $167.93 | 2021-2025 | Trodelvy |
| Incyte Corporation | $125.00 | 2019 | |
| Janssen Biotech, INC. | $97.37 | 2019-2023 | Erleada |
| Daiichi Sankyo INC. | $90.00 | 2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $64.82 | 2022-2025 | Opdualag |
| Regeneron Healthcare Solutions, INC. | $34.04 | 2024 | Libtayo |
| Acrotech Biopharma INC. | $31.64 | 2024 | Ryzneuta |
| Celgene Corporation | $31.10 | 2024-2025 | Reblozyl |
| Novartis Pharmaceuticals Corporation | $29.94 | 2025 | |
| Lilly USA, LLC | $22.26 | 2024 | |
| Amgen INC. | $13.40 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.17 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.72 | 2022 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$54,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Horkheimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.